MadeAi validated its graph-inference capability across seven visual formats, achieving approximately 98% accuracy on graph and chart-inferred values with 99% traced to the exact figure and supporting source sentence.

Public source

Publisher name

Public post

Important clinical evidence is often locked inside figures, not written in the text. Which chart type is the most difficult and time-consuming for your team to extract d…

Log in to read the full post

Company

MadeAi

Accelerating evidence synthesis with AI you can trust

Industry
Software Development
Location
Cambridge, US
Company size
11–50 employees

About MadeAi

MadeAi™, developed by CapeStart, is an AI platform that streamlines life sciences evidence synthesis workflows. Its flagship solution, MadeAi-LR, accelerates literature reviews by up to 60% while maintaining over 90% accuracy. MadeAi enables additional evidence synthesis workflows including GVDs, MIRs, CERs, and JCA assistance, among others. The platform combines advanced machine learning with human validation to ensure FDA and EMA compliance. MadeAi is headquartered in Cambridge, Massachusetts and supported by CapeStart’s global team of 600+ professionals.

See more

Latest activity

9 signals

Discover more

Similar public activity from other companies.

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.